ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
- Conditions
- Prostate Cancer
- Registration Number
- NCT00061126
- Lead Sponsor
- Abgenix
- Brief Summary
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 50
- Male 18 years of age or older
- Has tumor tissue available for diagnostics
- Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study
- ECOG score of 0 or 1
- Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent)
- Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed)
- Known to be HIV positive
- Myocardial infarction within one year prior to entering the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Stanford Medical Center
🇺🇸Stanford, California, United States
Advanced Research Institute
🇺🇸New Port Richey, Florida, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh Cancer Institute, Hillman Cancer Center
🇺🇸Pittsburgh, Pennsylvania, United States
Urology San Antonio Research
🇺🇸San Antonio, Texas, United States
University of Washington
🇺🇸Seattle, Washington, United States
Madigan Army Medical Center
🇺🇸Tacoma, Washington, United States
University of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States